Roche Holding AG (SWX:ROG)
Switzerland · Delayed Price · Currency is CHF 260.20
-0.10 (-0.04%)
Sep 1, 2025, 5:30 PM CET
Roche Holding AG Revenue
Roche Holding AG had revenue of 31.85B CHF in the half year ending June 30, 2025, with 4.03% growth. This brings the company's revenue in the last twelve months to 63.49B, up 4.80% year-over-year. In the year 2024, Roche Holding AG had annual revenue of 62.40B with 3.23% growth.
Revenue (ttm)
63.49B
Revenue Growth
+4.80%
P/S Ratio
3.52
Revenue / Employee
614.90K
Employees
103,249
Market Cap
223.57B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 62.40B | 1.95B | 3.23% |
| Dec 31, 2023 | 60.44B | -5.37B | -8.16% |
| Dec 31, 2022 | 65.81B | -36.00M | -0.05% |
| Dec 31, 2021 | 65.85B | 5.51B | 9.13% |
| Dec 31, 2020 | 60.34B | -3.41B | -5.35% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Novartis AG | 43.89B |
| Lonza Group AG | 7.09B |
| Galderma Group AG | 3.73B |
| Alcon | 7.97B |
| Sandoz Group AG | 8.42B |
| Straumann Holding AG | 2.58B |
| Sonova Holding AG | 3.87B |
| Ypsomed Holding AG | 748.87M |
Roche Holding AG News
- 2 days ago - Alnylam (ALNY) Advances with Roche on Phase 3 Cardiovascular Trial for Zilebesiran - GuruFocus
- 2 days ago - Roche and Alnylam advance zilebesiran into global phase III cardiovascular outcomes trial for ... - GuruFocus
- 2 days ago - Genentech and Alnylam Advance Zilebesiran Into Global Phase III Cardiovascular Outcomes Trial for People With Uncontrolled Hypertension - Business Wire
- 2 days ago - Roche and Alnylam advance zilebesiran into global phase III cardiovascular outcomes trial for people with uncontrolled hypertension - GlobeNewsWire
- 3 days ago - Analog Devices Chair & CEO Trades $5.09M In Company Stock - Benzinga
- 7 days ago - Roche's US subsidiary Genentech breaks ground on state-of-the-art manufacturing facility in North Carolina, USA - GlobeNewsWire
- 7 days ago - Genentech and Roche Break Ground on State-of-the-Art Manufacturing Facility in Holly Springs, North Carolina - Business Wire
- 9 days ago - “Walk in My Shoes” Spotlights the Invisible Struggles of People Living with Multiple Sclerosis (MS) – a Public Health Awareness Initiative by Roche in Collaboration with Multiple Sclerosis Society of India (MSSI) - Business Upturn